What do systematic reviews say?

Adjuvant chemotherapy vs no chemotherapy

The review found no eligible studies for this question.

• Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

TG4010 added to chemotherapy vs chemotherapy alone

The review found no eligible studies for this question.

• Therapeutic vaccines for advanced non‐small cell lung cancer 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Immune checkpoint inhibitors vs any first‐line chemotherapy

• Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 393 participants
  Moderate

Immune checkpoint inhibitors vs any second‐line chemotherapy

• Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 727 participants
  Low

Gemcitabine plus cisplatin vs S‐1 plus cisplatin

The review found no eligible studies for this question.

• Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Gemcitabine plus S‐1 vs S‐1

The review found no eligible studies for this question.

• Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Gemcitabine plus oxaliplatin vs best supportive care

The review found no eligible studies for this question.

• Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Gemcitabine plus vandetanib vs vandetanib

The review found no eligible studies for this question.

• Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Gemcitabine plus oxaliplatin vs 5‐fluorouracil plus cisplatin plus radiotherapy

The review found no eligible studies for this question.

• Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Gemcitabine plus mitomycin C vs capecitabine plus mitomycin C

The review found no eligible studies for this question.

• Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Autologous hematopoietic stem cell transplantation following high‐dose chemotherapy for nonrhabdomyosarcoma soft… 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

ALK inhibitor vs any cytotoxic chemotherapy

ALK inhibitor leads to lower health‐related quality of life: time to deterioration in composite… compared with any cytotoxic chemotherapy (high certainty).

• Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes only
  HR 0.52 [0.44, 0.6]
  5 studies · 1504 participants
  High